Mirador Analytics

  • Home
  • Health Data Compliance Services
    • Health Data Compliance Overview
    • The Health Data Compliance Team
    • Health Data Compliance Services
  • Global Drug Development
    • Core Capabilities and Services
    • The Global Drug Development Team
  • The View Platform
  • News & Insight
    • News
    • Insight Articles
  • Contact Us
  • Legal
    • Privacy Policy
    • Terms and Conditions
  • Home
  • Health Data Compliance Services
    • Health Data Compliance Overview
    • The Health Data Compliance Team
    • Health Data Compliance Services
  • Global Drug Development
    • Core Capabilities and Services
    • The Global Drug Development Team
  • The View Platform
  • News & Insight
    • News
    • Insight Articles
  • Contact Us
  • Legal
    • Privacy Policy
    • Terms and Conditions

News

Mirador Analytics Links with TGaS Advisors

9/18/2017

0 Comments

 

​TGaS Advisors Teams with UK’s Mirador Analytics to Bring a New Level of Forecasting to today’s Complex Biopharmaceutical Environment

From TGaS Advisors' Press Room
E. Norriton, Penn. and Melrose, UK. 9.14.17. Credible forecasts create hundreds of millions of dollars of additional value for biopharma companies and investors, according to research by TGaS Advisors, a benchmarking and advisory services firm for life sciences commercial operations. Understanding asset evaluation is considered a critical element of the drug commercialization process and a fundamental component underpinning global commercial strategy development. To enable life sciences companies to maximize both their asset development and strategic launch plans, TGaS has formed a partnership with Mirador Analytics, Ltd., a UK company with advanced global forecasting capabilities. The partnership makes  asset forecasting and benchmarking available as a holistic service offering to global biopharmaceutical organizations.

Read More
0 Comments

BioInformant Article: Asset Evaluation Tool

3/15/2017

 

Asset Evaluation Online Tool Launch Mention, BioInformant Research

The launch of our new online version of  the Asset Evaluation Tool has been shared via BioInformant Research.
BioInformant is the first and currently only market research firm specializing in the stem cell industry.

You can read the article on their website by clicking the link here: BioInformant: Asset Evaluation Tool Article

For further detail of the Asset Evaluation Online Tool, please use the "Contact Us" page or email directly via info@miradoranalytics.com

Asset Evaluation Tool: Online Version Launch

2/22/2017

 

​​Revolutionizing Asset Evaluation

Picture
We’re delighted to let you know that we’ve launched an online version of our prevalence-based Asset Evaluation Tool.

If you’re engaged in New Product Planning, Drug Development, Launch Planning, Portfolio Prioritization, Life Cycle Management or working towards a specific transaction (e.g. license and/or investment), I’d love to chat with you and explore how the Asset Evaluation Tool could support you through these processes. 

With online access via an annual license, unlimited remote asset forecasting is now available, providing you with greater forecasting freedom and flexibility. Mirador Analytics’ Asset Evaluation Tool is perfectly positioned to assist you with strategic decision making, optimizing value and assessing risk. Should you require assistance with inputs into the Asset Evaluation Tool, our experienced consulting team can support here. If required, we can also build a bespoke Forecasting Tool to match your company’s precise specifications.
Drug development and commercialization is an uncertain process. As a commercialization catalyst, Mirador Analytics helps foster the drug innovation process and provides drug commercialization assessment and launch planning services to biopharma SMEs around the world. With this in mind, alongside our Asset Evaluation services, we can also assist with Portfolio Prioritization, Life Cycle Management and Business Development Transactional Services.

Mirador Analytics is unique in comparison to other analytics and consulting organizations. We have extensive experience in the pharmaceutical sector and our team members have worked in similar senior-level roles to our clients. Alongside this, by combining both analytical and consultancy services we deliver relevant industry-specific outputs during every interaction with you.
​
To learn more about the Asset Evaluation Tool or to set up a complimentary trial, please get in touch via the contact us page.
Contact us

Portfolio Prioritisation: Are you scanning the horizon for the best portfolio fit?

1/31/2017

 

Having a clear view of where you want to go


Read More

Thought Leader Identification

12/1/2016

 

​Rethinking KOL and Thought Leader Identification and Interactions


Read More

    Mirador Analytics

    Check out our news section for; our previous articles, events we are attending and other Mirador Analytics relevant updates. 

    GET IN TOUCH

    Archives

    September 2018
    May 2018
    March 2018
    February 2018
    January 2018
    September 2017
    June 2017
    May 2017
    March 2017
    February 2017
    January 2017
    December 2016

    Categories

    All
    Asset Valuation
    Benchmarking
    Compliance Services
    #datafest18
    DataTalentScotland
    Events
    Forecasting
    Health Data
    HIPAA
    Identification Services
    LCM Strategy And Portfolio Planning
    Partnerships
    Services
    Tools And Services

United Kingdom

Jamie Blackport
CEO

Tel: +44 (0)1896 802100
© 2018. Mirador Analytics Limited. All Rights Reserved.